ScholarIQanswers from OpenAlex & ORCID
Richard E. Champlin
ResearcherPublications, citations & collaboration network
Richard E. Champlin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard E. Champlin have?
ScholarIQindexed works
Richard E. Champlin has 2,079 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard E. Champlin have?
ScholarIQcitation count
Richard E. Champlin has 77,552 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard E. Champlin?
ScholarIQh-index
Richard E. Champlin has an h-index of 148 in OpenAlex.
What is the i10-index of Richard E. Champlin?
ScholarIQi10-index
Richard E. Champlin has an i10-index of 803 in OpenAlex.
What is the ORCID of Richard E. Champlin?
ScholarIQorcid
The ORCID for Richard E. Champlin is on the source record.
What is the OpenAlex record for Richard E. Champlin?
ScholarIQopenalex
The OpenAlex for Richard E. Champlin is on the source record.
What are the most-cited papers on Richard E. Champlin?
ScholarIQmost cited works
Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture
Marcos de Lima, Ian McNiece, Simon N. Robinson, Mark F. Munsell, Mary Eapen, Mary M. Horowitz, Amin M. Alousi, Rima M. Saliba, John D. McMannis, Indreshpal Kaur, Partow Kebriaei, Simrit Parmar, Uday Popat, Chitra Hosing, Richard E. Champlin, Catherine M. Bollard, Jeffrey J. Molldrem, Roy B. Jones, Yago Nieto, Börje S. Andersson, Nina Shah, Betül Oran, Laurence J.N. Cooper, Laura L. Worth, Muzaffar H. Qazilbash, Martin Körbling, Gabriela Rondón, Stefan O. Ciurea, Doyle Bosque, I. Maewal, Paul J. Simmons, Elizabeth J. Shpall
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Navneet S. Majhail, Stephanie Farnia, Paul A. Carpenter, Richard E. Champlin, Stephen W. Crawford, David I. Marks, James Omel, Paul J. Orchard, Jeanne Palmer, Wael Saber, Bipin N. Savani, Paul Veys, Christopher Bredeson, Sergio Giralt, C. Frederick LeMaistre
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation
Apostolia M. Tsimberidou, Susan O’Brien, Issa F. Khouri, Francis J. Giles, Hagop M. Kantarjian, Richard E. Champlin, Sijin Wen, Kim‐Anh Do, Susan Smith, Susan Lerner, Emil J. Freireich, Michael J. Keating
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica M McCarty, Indreshpal Kaur, Eric Yvon, Hila Shaim, Muharrem Müftüoğlu, Enli Liu, Robert Z. Orlowski, Laurence J.N. Cooper, Dean A. Lee, Simrit Parmar, Kai Cao, Catherine Sobieiski, Rima M. Saliba, Chitra Hosing, Sairah Ahmed, Yago Nieto, Qaiser Bashir, Krina K. Patel, Catherine M. Bollard, Muzaffar H. Qazilbash, Richard E. Champlin, Katy Rezvani, Elizabeth J. Shpall